株式会社極東書店トップ ＞ 商品一覧 ＞ Anticancer Activity in Heterocyclic Organic Structures: A Pathway to Novel Drug Development Part 1.
商品詳細
Anticancer Activity in Heterocyclic Organic Structures: A Pathway to Novel Drug Development Part 1.
・ISBN 978-1-041-10058-4 hard GB£ 171.99
￥54,486.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
| 著者・編者 | El Mchichi, Larbi / Bouachrine, Mohammed / Lakhlifi, Tahar, |
|---|---|
| シリーズ | (New Directions in Organic & Biological Chemistry) |
| 出版社 | (CRC Press, UK) |
| 出版年月 | 2025 |
| ページ数 | 166 pp. |
| 言語 | ENG |
| ニュース番号 | ＜A04-52388＞ |
解説
This new volume in New Directions in Organic & Biological Chemistry, explores the development of cancer therapeutics, focusing on molecular chemistry and advanced drug design approaches. Written by experts in theoretical chemistry and molecular chemistry, they bridge the gap between theoretical chemistry, molecular biology, and drug development. In Part I, they focus on the fundamental properties of heterocyclic compounds and innovative methodologies being employed to enhance therapeutic potential. By exploring various classes of heterocyclic compounds and diverse anticancer mechanisms, this book provides a valuable resource for researchers, pharmaceutical scientists, and oncologists.
Key Features
- Provides an overview of computational approaches used in drug discovery, including molecular docking, QSAR, and virtual screening
- Focuses on the theoretical and practical aspects of these techniques, with applications across various therapeutic areas, including cancer
- Addresses the challenges in translating scientific research into effective treatments, offering insights into overcoming common obstacles in the development process
- These compounds represent a significant opportunity for the pharmaceutical industry to provide more effective and tailored cancer treatments, further driving market growth
- The breadth of the market for heterocyclic anticancer agents is vast and continues to expand as scientific advancements uncover new therapeutic targets